Granules

Granules India Limited is a vertically integrated, high-growth pharmaceutical manufacturing company headquartered in Hyderabad, India.

Established in 1984, Granules India has evolved from a single-product manufacturer into a multifaceted global pharmaceutical entity. The company specialises in producing Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), and Finished Dosages (FDs). With a commitment to manufacturing excellence, process innovation, and regulatory expertise, Granules India serves over 300 customers across 80+ countries. The company's vertically integrated model ensures a seamless value chain, enhancing cost-effectiveness and quality control. Granules India's facilities are designed for large-scale production, including the world's largest PFI plant in Gagillapur, with an industry-leading batch size of 24,640 TPA. A dedicated research and development team continually strives to develop diverse, cost-effective pharmaceutical solutions.

Key Products and Services:

• Active Pharmaceutical Ingredients (APIs): High-quality APIs in key therapeutic categories, including Paracetamol, Ibuprofen, Metformin, Methocarbamol, and Guaifenesin.

• Pharmaceutical Formulation Intermediates (PFIs): Granulated products ready for tablet compression, facilitating efficient and consistent tablet manufacturing.

• Finished Dosages (FDs): A range of dosage forms such as tablets, caplets, and press-fit capsules, available in bulk, blister packs, and bottles.

Granules India is led by a seasoned team of professionals, including Chairman and Managing Director Dr. Krishna Prasad Chigurupati, Joint Managing Director and Chief Executive Officer Dr. K.V.S. Ram Rao, and Executive Directors Mrs. Uma Devi Chigurupati, Ms. Priyanka Chigurupati, and Mr. Harsha Chigurupati. Their collective expertise and vision drive the company's mission to provide access to safe, effective, and affordable medicines globally. As Granules India continues to expand its global footprint, it remains dedicated to innovation, sustainability, and excellence in the pharmaceutical industry.